Ranibizumab vs. aflibercept for wet age-related macular degeneration: Network meta-analysis to understand the value of reduced frequency dosing

Current Medical Research and Opinion

Volumn 31, Issue 11, 2015, Pages 2031-2042

  Szabo, Shelagh M ^a   Hedegaard, Morten ^b   Chan, Keith ^a   Thorlund, Kristian ^a   Christensen, Robin ^c   Vorum, Henrik ^d   Jansen, Jeroen P ^e  

^a Redwood Outcomes   (Canada)

^b Novartis Healthcare ^*  (Denmark)

^c Copenhagen University Hospital ^*  (Denmark)

^d AALBORG UNIVERSITY HOSPITAL   (Denmark)

^e Redwood Outcomes   (United States)

Author keywords

Age related macular degeneration; Network meta analysis; Systematic review; Vascular endothelial growth factor inhibitors

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; PEGAPTANIB; PLACEBO; RANIBIZUMAB; HYBRID PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR;

AGE RELATED MACULAR DEGENERATION; ARTICLE; BAYESIAN LEARNING; BEST CORRECTED VISUAL ACUITY; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; LOGISTIC REGRESSION ANALYSIS; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAMPLE SIZE; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL ACUITY; VISUAL ACUITY CHART; WET AGE RELATED MACULAR DEGENERATION; ANTAGONISTS AND INHIBITORS; BAYES THEOREM; COMPARATIVE STUDY; WET MACULAR DEGENERATION;

BAYES THEOREM; HUMANS; RANIBIZUMAB; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84947493343     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2015.1084909     Document Type: Article

References (36)

1. Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of age-related macular degeneration. Am J Ophthalmol 2004; 137: 486-95
2. Grisanti S, Tatar O. The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration. Prog Retin Eye Res 2008; 27: 372-90
3. Brown DM, Heier JS, Ciulla T, et al. Primary endpoint results of a phase II study of vascular endothelial growth factor trap-eye in wet age-related macular degeneration. Ophthalmology 2011; 118: 1089-97
4. Busbee BG, Ho AC, Brown DM, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 2013; 120: 1046-56
5. Chakravarthy U, Harding SP, Rogers CA, et al. Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet 2013; 382: 1258-67
6. Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012; 119: 1399-411
7. The CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011; 364: 1897-908
8. Heier JS, Boyer D, Nguyen QD, et al. The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing. Ophthalmology 2011; 118: 1098-106
9. Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology 2012; 119: 2537-48
10. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012; 119: 1388-98
11. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-31
12. Bressler NM, Bressler SB, Haynes LA, et al. Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration: four-year results of an open-label extension of 2 randomized clinical trials: TAP Report No. 7. Arch Ophthalmol 2005; 123: 1283-5
13. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials. Arch Ophthalmol 1993; 111: 1200-9
14. Brown DM, Michels M, Kaiser PK, et al. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009; 116: 57-65.e55
15. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007; 143: 566-83
16. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009; 148: 43-58 e41
17. Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. Am J Ophthalmol 2012; 153: 209-13 e202
18. Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ 2005; 331: 897-900
19. Jansen JP, Fleurence R, Devine B, et al. Interpreting indirect treatment comparisons and network meta-Analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 2011; 14: 417-28
20. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. Stat Med 2004; 23: 3105-24
21. Fadda V, Maratea D, Trippoli S, Messori A. Treatments for macular degeneration: summarising evidence using network meta-Analysis. Br J Ophthalmol 2011; 95: 1476-7
22. Virgili G, Novielli N, Menchini F, et al. Pharmacological treatments for neovascular age-related macular degeneration: can mixed treatment comparison meta-Analysis be useful? Curr Drug Targets 2011; 12: 212-20
23. EMA. Eylea, INN-Aflibercept: Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002392/WC500135815.pdf [Last accessed 29 April 2015]
24. EMA. Lucentis, INN-ranibizumab: Summary of Product Characteristics. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000715/WC500043546.pdf [Last accessed 29 April 2015]
25. Genentech. Lucentis (ranibizumab injection)-Full Prescribing Information. 2015. Available at: http://www.gene.com/download/pdf/lucentis-prescribing.pdf [Last accessed 21 May 2015]
26. Reich O, Bachmann LM, Faes L, et al. Anti-VEGF treatment patterns and associated health care costs in Switzerland: findings using real-world claims data. Risk Manag Healthc Pol 2015; 8: 55-62
27. Kiss S, Dugel PU, Wilson K, et al. Treatment patterns and associated costs of anti-VEGF therapy for neovascular age-related macular degeneration. Paper presented at: Association for Research in Vision and Ophthalmology, Denver USA, April 26-30, 2015
28. Stewart MW, Rosenfeld PJ. Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol 2008; 92: 667-8
29. Jansen JP, Vieira MC, Cope S. Network meta-Analysis of longitudinal data using fractional polynomials. Stat Med 2015; 34: 2294-311
30. Hodgson RBT, Fleetwood K, Edwards M, Glanville J. Indirect Treatment Comparison of Lucentis for Wet Age Related Macular Degeneration. York Health Economics Consortium, June 2014
31. Malcolm WAHR, Glanville J, Barata T, Fleetwood K. Indirect treatment comparison of interventions for neovascular (wet) age-related macular degeneration (wet AMD). Paper presented at: ISPOR 20th Annual International Meeting, 2015, Philadelphia, PA, USA
32. Dias S, Welton NJ, Sutton AJ, Ades AE. NICE DSU Technical Support Document 2: a generalised linear modelling framework for pairwise and network meta-Analysis of randomised controlled trials. 2011. Available at: http://www.nicedsu.org.uk/ [last accessed June 30 2015]
33. Dias S, Sutton AJ, Ades AE, Welton NJ. Evidence synthesis for decision making 2: a generalized linear modeling framework for pairwise and network meta-Analysis of randomized controlled trials. Med Decis Making 2013; 33: 607-17
34. Dias S, Welton NJ, Sutton AJ, et al. Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials. Med Decis Making 2013; 33: 641-56
35. Spiegelhalter D, Thomas A, Best N, Lunn D. WinBUGS user manual version 1.4. 2003
36. Brooks SPGA. General methods for monitoring convergence of iterative simulations. J Computational Graphics Stat 1998; 7: 434-55